BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of 10,340,000 shares of its common stock. Each share of common stock is being sold at a price of $12.09. The aggregate gross proceeds of the offering are expected to be approximately $125 million,
Business Wire Stock Sale/Buyback News